SBIR Phase II: High-Throughput Specific Cell Loading by Optoinjection

Information

  • NSF Award
  • 0321740
Owner
  • Award Id
    0321740
  • Award Effective Date
    11/1/2003 - 20 years ago
  • Award Expiration Date
    10/31/2007 - 16 years ago
  • Award Amount
    $ 1,024,000.00
  • Award Instrument
    Standard Grant

SBIR Phase II: High-Throughput Specific Cell Loading by Optoinjection

This SBIR Phase II project proposes to develop a novel technology for laser-enabled analysis and processing (LEAP) of living cells. The ability to load cells with compounds is critical in many areas of research and medicine such as drug discovery and gene therapy. Current methods have limitations with respect to specificity, efficiency, toxicity, and/or throughput. Optoinjection is a novel and versatile procedure for cell loading that has been demonstrated in a few laboratories. Unfortunately, this is a slow, laborious procedure carried out on specialized microscopes. Oncosis has developed the LEAP platform for high-speed cell imaging and purification via lethal laser effects on unwanted cells. Phase I results demonstrated feasibility for using the LEAP platform to implement optoinjection in a high-throughput, cell-specific manner that would enable the commercialization of this novel form of cell loading. Phase II studies are proposed to optimize and implement optoinjection in biologically relevant experimental systems, resulting in data supporting this powerful new tool for the analysis and manipulation of living cells within a physiological environment. The instrument design will then be configured for successful commercial manufacturing, and further improvements in capabilities will be pursued in order to maintain market leadership and to expand into other markets.<br/><br/>The commercial application of this project is in the areas of cell-based life science research and drug discovery. Over $ 2.6 billion was spent during 2001 on research instrumentation in academic life science research and commercial drug discovery, and growth to $ 5.3 billion by 2005 has been forecasted. For the specific application of optoinjection, LEAP provides many advantages over current techniques including simplicity, robustness, efficiency, speed, high viability, and specificity. The commercial opportunity for this platform is therefore significant, as is the scientific enablement of experimentation that is not currently possible.

  • Program Officer
    Ali Andalibi
  • Min Amd Letter Date
    10/17/2003 - 20 years ago
  • Max Amd Letter Date
    7/17/2006 - 18 years ago
  • ARRA Amount

Institutions

  • Name
    Cyntellect, Inc
  • City
    San Diego
  • State
    CA
  • Country
    United States
  • Address
    6199 Cornerstone Court
  • Postal Code
    921214740
  • Phone Number
    6195501770

Investigators

  • First Name
    Glenn
  • Last Name
    Sasaki
  • Email Address
    gsasaki@cyntellect.com
  • Start Date
    10/17/2003 12:00:00 AM

FOA Information

  • Name
    Health
  • Code
    203000
  • Name
    Biomaterials-Short & Long Terms
  • Code
    510402